Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1997 Jun;71(6):4347–4355. doi: 10.1128/jvi.71.6.4347-4355.1997

A pulmonary influenza virus infection in SCID mice can be cured by treatment with hemagglutinin-specific antibodies that display very low virus-neutralizing activity in vitro.

K Mozdzanowska 1, M Furchner 1, G Washko 1, J Mozdzanowski 1, W Gerhard 1
PMCID: PMC191651  PMID: 9151823

Abstract

We have previously shown that a pulmonary influenza virus infection in SCID mice can be cured by treatment with monoclonal antibodies (MAbs) specific for the viral transmembrane protein hemagglutinin (HA) but not for matrix 2. Since both types of MAbs react with infected cells but only the former neutralizes the virus, it appeared that passive MAbs cured by neutralization of progeny virus rather than reaction with infected host cells. To prove this, we selected a set of four HA-specific MAbs, all of the immunoglobulin G2a isotype, which reacted well with native HA expressed on infected cells yet differed greatly (>10,000-fold) in virus neutralization (VN) activity in vitro, apparently because of differences in antibody avidity and accessibility of the respective determinants on the HA of mature virions. Since the VN activities of these MAbs in vitro were differentially enhanced by serum components, we determined their prophylactic activities in vivo and used them as measures of their actual VN activities in vivo. The comparison of therapeutic and prophylactic activities indicated that these MAbs cured the infection to a greater extent by VN activity (which was greatly enhanced in vivo) and to a lesser extent by reaction with infected host cells. Neither complement- nor NK cell-dependent mechanisms were involved in the MAb-mediated virus clearance.

Full Text

The Full Text of this article is available as a PDF (292.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Becht H., Huang R. T., Fleischer B., Boschek C. B., Rott R. Immunogenic properties of the small chain HA2 of the haemagglutinin of influenza viruses. J Gen Virol. 1984 Jan;65(Pt 1):173–183. doi: 10.1099/0022-1317-65-1-173. [DOI] [PubMed] [Google Scholar]
  2. Beebe D. P., Schreiber R. D., Cooper N. R. Neutralization of influenza virus by normal human sera: mechanisms involving antibody and complement. J Immunol. 1983 Mar;130(3):1317–1322. [PubMed] [Google Scholar]
  3. Benne C. A., Kraaijeveld C. A., van Strijp J. A., Brouwer E., Harmsen M., Verhoef J., van Golde L. M., van Iwaarden J. F. Interactions of surfactant protein A with influenza A viruses: binding and neutralization. J Infect Dis. 1995 Feb;171(2):335–341. doi: 10.1093/infdis/171.2.335. [DOI] [PubMed] [Google Scholar]
  4. Boere W. A., Benaissa-Trouw B. J., Harmsen T., Erich T., Kraaijeveld C. A., Snippe H. Mechanisms of monoclonal antibody-mediated protection against virulent Semliki Forest virus. J Virol. 1985 May;54(2):546–551. doi: 10.1128/jvi.54.2.546-551.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brandriss M. W., Schlesinger J. J., Walsh E. E., Briselli M. Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. J Gen Virol. 1986 Feb;67(Pt 2):229–234. doi: 10.1099/0022-1317-67-2-229. [DOI] [PubMed] [Google Scholar]
  6. Buchmeier M. J., Welsh R. M., Dutko F. J., Oldstone M. B. The virology and immunobiology of lymphocytic choriomeningitis virus infection. Adv Immunol. 1980;30:275–331. doi: 10.1016/s0065-2776(08)60197-2. [DOI] [PubMed] [Google Scholar]
  7. Burns J. W., Siadat-Pajouh M., Krishnaney A. A., Greenberg H. B. Protective effect of rotavirus VP6-specific IgA monoclonal antibodies that lack neutralizing activity. Science. 1996 Apr 5;272(5258):104–107. doi: 10.1126/science.272.5258.104. [DOI] [PubMed] [Google Scholar]
  8. Caton A. J., Brownlee G. G., Yewdell J. W., Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell. 1982 Dec;31(2 Pt 1):417–427. doi: 10.1016/0092-8674(82)90135-0. [DOI] [PubMed] [Google Scholar]
  9. Cobbold S. P., Jayasuriya A., Nash A., Prospero T. D., Waldmann H. Therapy with monoclonal antibodies by elimination of T-cell subsets in vivo. Nature. 1984 Dec 6;312(5994):548–551. doi: 10.1038/312548a0. [DOI] [PubMed] [Google Scholar]
  10. Crowe J. E., Jr, Murphy B. R., Chanock R. M., Williamson R. A., Barbas C. F., 3rd, Burton D. R. Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice. Proc Natl Acad Sci U S A. 1994 Feb 15;91(4):1386–1390. doi: 10.1073/pnas.91.4.1386. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Dietzschold B., Kao M., Zheng Y. M., Chen Z. Y., Maul G., Fu Z. F., Rupprecht C. E., Koprowski H. Delineation of putative mechanisms involved in antibody-mediated clearance of rabies virus from the central nervous system. Proc Natl Acad Sci U S A. 1992 Aug 1;89(15):7252–7256. doi: 10.1073/pnas.89.15.7252. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fujinami R. S., Norrby E., Oldstone M. B. Antigenic modulation induced by monoclonal antibodies: antibodies to measles virus hemagglutinin alters expression of other viral polypeptides in infected cells. J Immunol. 1984 May;132(5):2618–2621. [PubMed] [Google Scholar]
  13. Fujisawa H., Tsuru S., Taniguchi M., Zinnaka Y., Nomoto K. Protective mechanisms against pulmonary infection with influenza virus. I. Relative contribution of polymorphonuclear leukocytes and of alveolar macrophages to protection during the early phase of intranasal infection. J Gen Virol. 1987 Feb;68(Pt 2):425–432. doi: 10.1099/0022-1317-68-2-425. [DOI] [PubMed] [Google Scholar]
  14. Gerhard W., Yewdell J., Frankel M. E., Webster R. Antigenic structure of influenza virus haemagglutinin defined by hybridoma antibodies. Nature. 1981 Apr 23;290(5808):713–717. doi: 10.1038/290713a0. [DOI] [PubMed] [Google Scholar]
  15. Hartley C. A., Jackson D. C., Anders E. M. Two distinct serum mannose-binding lectins function as beta inhibitors of influenza virus: identification of bovine serum beta inhibitor as conglutinin. J Virol. 1992 Jul;66(7):4358–4363. doi: 10.1128/jvi.66.7.4358-4363.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hartshorn K. L., Sastry K., Brown D., White M. R., Okarma T. B., Lee Y. M., Tauber A. I. Conglutinin acts as an opsonin for influenza A viruses. J Immunol. 1993 Dec 1;151(11):6265–6273. [PubMed] [Google Scholar]
  17. Hicks J. T., Ennis F. A., Kim E., Verbonitz M. The importance of an intact complement pathway in recovery from a primary viral infection: influenza in decomplemented and in C5-deficient mice. J Immunol. 1978 Oct;121(4):1437–1445. [PubMed] [Google Scholar]
  18. Hunt A. R., Short W. A., Johnson A. J., Bolin R. A., Roehrig J. T. Synthetic peptides of the E2 glycoprotein of Venezuelan equine encephalomyelitis virus. II. Antibody to the amino terminus protects animals by limiting viral replication. Virology. 1991 Nov;185(1):281–290. doi: 10.1016/0042-6822(91)90775-7. [DOI] [PubMed] [Google Scholar]
  19. Kavaler J., Caton A. J., Staudt L. M., Schwartz D., Gerhard W. A set of closely related antibodies dominates the primary antibody response to the antigenic site CB of the A/PR/8/34 influenza virus hemagglutinin. J Immunol. 1990 Oct 1;145(7):2312–2321. [PubMed] [Google Scholar]
  20. Kida H., Brown L. E., Webster R. G. Biological activity of monoclonal antibodies to operationally defined antigenic regions on the hemagglutinin molecule of A/Seal/Massachusetts/1/80 (H7N7) influenza virus. Virology. 1982 Oct 15;122(1):38–47. doi: 10.1016/0042-6822(82)90375-0. [DOI] [PubMed] [Google Scholar]
  21. Lefrancois L. Protection against lethal viral infection by neutralizing and nonneutralizing monoclonal antibodies: distinct mechanisms of action in vivo. J Virol. 1984 Jul;51(1):208–214. doi: 10.1128/jvi.51.1.208-214.1984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Levine B., Hardwick J. M., Trapp B. D., Crawford T. O., Bollinger R. C., Griffin D. E. Antibody-mediated clearance of alphavirus infection from neurons. Science. 1991 Nov 8;254(5033):856–860. doi: 10.1126/science.1658936. [DOI] [PubMed] [Google Scholar]
  23. Liebert U. G., Schneider-Schaulies S., Baczko K., ter Meulen V. Antibody-induced restriction of viral gene expression in measles encephalitis in rats. J Virol. 1990 Feb;64(2):706–713. doi: 10.1128/jvi.64.2.706-713.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Mathews J. H., Roehrig J. T., Trent D. W. Role of complement and the Fc portion of immunoglobulin G in immunity to Venezuelan equine encephalomyelitis virus infection with glycoprotein-specific monoclonal antibodies. J Virol. 1985 Sep;55(3):594–600. doi: 10.1128/jvi.55.3.594-600.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. McCullough K. C. Monoclonal antibodies: implications for virology. Brief review. Arch Virol. 1986;87(1-2):1–36. doi: 10.1007/BF01310540. [DOI] [PubMed] [Google Scholar]
  26. Moskophidis D., Löhler J., Lehmann-Grube F. Antiviral antibody-producing cells in parenchymatous organs during persistent virus infection. J Exp Med. 1987 Mar 1;165(3):705–719. doi: 10.1084/jem.165.3.705. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Palladino G., Mozdzanowska K., Washko G., Gerhard W. Virus-neutralizing antibodies of immunoglobulin G (IgG) but not of IgM or IgA isotypes can cure influenza virus pneumonia in SCID mice. J Virol. 1995 Apr;69(4):2075–2081. doi: 10.1128/jvi.69.4.2075-2081.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Pincus S. H., Cole R., Ireland R., McAtee F., Fujisawa R., Portis J. Protective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus. J Virol. 1995 Nov;69(11):7152–7158. doi: 10.1128/jvi.69.11.7152-7158.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Prince G. A., Hemming V. G., Horswood R. L., Baron P. A., Chanock R. M. Effectiveness of topically administered neutralizing antibodies in experimental immunotherapy of respiratory syncytial virus infection in cotton rats. J Virol. 1987 Jun;61(6):1851–1854. doi: 10.1128/jvi.61.6.1851-1854.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Rector J. T., Lausch R. N., Oakes J. E. Use of monoclonal antibodies for analysis of antibody-dependent immunity to ocular herpes simplex virus type 1 infection. Infect Immun. 1982 Oct;38(1):168–174. doi: 10.1128/iai.38.1.168-174.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Scherle P. A., Palladino G., Gerhard W. Mice can recover from pulmonary influenza virus infection in the absence of class I-restricted cytotoxic T cells. J Immunol. 1992 Jan 1;148(1):212–217. [PubMed] [Google Scholar]
  32. Schlesinger J. J., Chapman S. Neutralizing F(ab')2 fragments of protective monoclonal antibodies to yellow fever virus (YF) envelope protein fail to protect mice against lethal YF encephalitis. J Gen Virol. 1995 Jan;76(Pt 1):217–220. doi: 10.1099/0022-1317-76-1-217. [DOI] [PubMed] [Google Scholar]
  33. Schmaljohn A. L., Johnson E. D., Dalrymple J. M., Cole G. A. Non-neutralizing monoclonal antibodies can prevent lethal alphavirus encephalitis. Nature. 1982 May 6;297(5861):70–72. doi: 10.1038/297070a0. [DOI] [PubMed] [Google Scholar]
  34. Staudt L. M., Gerhard W. Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. I. Significant variation in repertoire expression between individual mice. J Exp Med. 1983 Feb 1;157(2):687–704. doi: 10.1084/jem.157.2.687. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Stein-Streilein J., Bennett M., Mann D., Kumar V. Natural killer cells in mouse lung: surface phenotype, target preference, and response to local influenza virus infection. J Immunol. 1983 Dec;131(6):2699–2704. [PubMed] [Google Scholar]
  36. Stein-Streilein J., Guffee J. In vivo treatment of mice and hamsters with antibodies to asialo GM1 increases morbidity and mortality to pulmonary influenza infection. J Immunol. 1986 Feb 15;136(4):1435–1441. [PubMed] [Google Scholar]
  37. Taylor G., Stott E. J., Bew M., Fernie B. F., Cote P. J., Collins A. P., Hughes M., Jebbett J. Monoclonal antibodies protect against respiratory syncytial virus infection in mice. Immunology. 1984 May;52(1):137–142. [PMC free article] [PubMed] [Google Scholar]
  38. Virgin H. W., 4th, Bassel-Duby R., Fields B. N., Tyler K. L. Antibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing). J Virol. 1988 Dec;62(12):4594–4604. doi: 10.1128/jvi.62.12.4594-4604.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Wiley D. C., Skehel J. J. The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem. 1987;56:365–394. doi: 10.1146/annurev.bi.56.070187.002053. [DOI] [PubMed] [Google Scholar]
  40. Wilson I. A., Cox N. J. Structural basis of immune recognition of influenza virus hemagglutinin. Annu Rev Immunol. 1990;8:737–771. doi: 10.1146/annurev.iy.08.040190.003513. [DOI] [PubMed] [Google Scholar]
  41. Wölfel T., Van Pel A., De Plaen E., Lurquin C., Maryanski J. L., Boon T. Immunogenic (tum-) variants obtained by mutagenesis of mouse mastocytoma P815. VIII. Detection of stable transfectants expressing a tum- antigen with a cytolytic T cell stimulation assay. Immunogenetics. 1987;26(3):178–187. doi: 10.1007/BF00365909. [DOI] [PubMed] [Google Scholar]
  42. van oud Alblas A. B., van Furth R. Origin, Kinetics, and characteristics of pulmonary macrophages in the normal steady state. J Exp Med. 1979 Jun 1;149(6):1504–1518. doi: 10.1084/jem.149.6.1504. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES